[Basic studies on IL-2 gene therapy for head and neck carcinoma]

Area of Science:

• Oncology
• Gene Therapy
• Immunotherapy

Context:

• Head and neck carcinomas present a significant therapeutic challenge.
• Current treatment options for these cancers have limitations.
• Developing novel immunotherapies is crucial for improving patient outcomes.

Purpose:

• To investigate the feasibility of interleukin-2 (IL-2) gene transduction into tumor cells for head and neck cancer immunotherapy.
• To evaluate the efficacy of IL-2 gene-modified tumor cells in preclinical models.

Summary:

• The interleukin-2 (IL-2) gene was successfully transduced into KB cells (a head and neck carcinoma cell line) using a herpes simplex viral (HSV) amplicon vector, creating KB/IL-2 cells that produced high levels of IL-2.
• Culture supernatant from KB/IL-2 cells enhanced the cytotoxic activity of human peripheral blood mononuclear cells (PBMC) against KB cells.
• In vivo studies demonstrated that nude mice transplanted with KB/IL-2 cells showed elevated IL-2 and interferon-gamma (IFN-gamma) levels, enhanced spleen cell cytotoxic activity, and significant tumor regression, with 3 out of 5 mice cured and surviving over 120 days, unlike control groups.

Impact:

• This study provides preclinical evidence for a novel gene therapy approach using IL-2 gene-transduced tumor cells as a potential immunotherapy for head and neck carcinomas.
• The findings suggest that IL-2-mediated stimulation of effector cells and synergistic effects of IFN-gamma contribute to tumor rejection.
• Successful tumor eradication in a significant portion of treated mice highlights the potential of this therapeutic strategy.